# Gilead Sciences (GILD) — Analyst Forecast

GILD · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gild/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 23 | 6 | 1 | 30 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $126.00 | $154.33 | $175.00 | 9 |

Last price $157.37 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 8, 2026 | Cantor Fitzgerald | Maintained | Overweight | $155.00 |
| Oct 8, 2026 | RBC Capital | Maintained | Sector Perform | $126.00 |
| Oct 7, 2026 | JP Morgan | Maintained | Overweight | $170.00 |
| Oct 7, 2026 | Truist Securities | Maintained | Buy | $158.00 |
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | $163.00 |
| Sep 10, 2026 | HSBC | Maintained | Buy | $175.00 |
| Aug 5, 2026 | Needham | Maintained | Buy | $170.00 |
| Aug 5, 2026 | Cantor Fitzgerald | Maintained | Overweight | $155.00 |
| Aug 5, 2026 | RBC Capital | Maintained | Sector Perform | $123.00 |
| Jul 29, 2026 | Barclays | Maintained | Equal-Weight | $145.00 |
| Jul 27, 2026 | Morgan Stanley | Maintained | Overweight | $165.00 |
| Jul 21, 2026 | Leerink Partners | Downgraded | Outperform → Market Perform | $127.00 |
| Jul 8, 2026 | Morgan Stanley | Maintained | Overweight | $166.00 |
| Jul 7, 2026 | Truist Securities | Maintained | Buy | $156.00 |
| Jul 7, 2026 | RBC Capital | Maintained | Sector Perform | $120.00 |
| Jul 6, 2026 | HSBC | Upgraded | Hold → Buy | $155.00 |
| Jul 6, 2026 | Cantor Fitzgerald | Maintained | Overweight | $155.00 |
| Jun 16, 2026 | Cantor Fitzgerald | Maintained | Overweight | $155.00 |
| May 20, 2026 | Maxim Group | Upgraded | Hold → Buy | $165.00 |
| May 8, 2026 | Truist Securities | Maintained | Buy | $157.00 |

## Frequently Asked Questions

### What is the price target for GILD stock?

The average 12-month analyst price target for Gilead Sciences (GILD) is $154.33, with a high estimate of $175.00 and a low of $126.00, across 9 analysts.

### Is GILD a buy, sell, or hold?

Analysts covering Gilead Sciences currently average a Buy rating: 23 buy, 6 hold and 1 sell, from 30 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for GILD?

The average price target of $154.33 implies 1.93% downside from the last price of $157.37.

### What is the latest analyst rating on GILD?

On Oct 8, 2026, Cantor Fitzgerald maintained Gilead Sciences at Overweight with a price target of $155.00.

## Similar Stocks

- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [REGN](https://www.lighthorse.io/tickers/regn) — Regeneron Pharmaceuticals, Inc. - Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [LGND](https://www.lighthorse.io/tickers/lgnd) — Ligand Pharmaceuticals Incorporated - Common Stock
- [VIR](https://www.lighthorse.io/tickers/vir) — Vir Biotechnology, Inc. - Common Stock
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).